No clear answer
Cell therapies and tolerisation: slow disability worsening in relapsing MS
relapsing MS · Cell therapies and tolerisation
Trials have tried this, but none was a controlled phase 2 or 3 trial with a readable result.
- Trials
- 3
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 24
No controlled trial has reported a result yet.
Other linked trials: 3
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 3
These linked trials do not set the status.
- HBMS01Result was for a different measure
Phase 2 · 2021 · Placebo-controlled
- A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMSStopped, other reason
Phase 1/2 · 2015 · Not randomised
- A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMSResult in a paper, not read yet
Phase 1/2 · 2015 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Status changed from Promising to No clear answer
- 2026-10-27First listed as Promising
Related hypotheses
- Cell therapies and tolerisation: slow disability worsening in primary progressive MS
- Cell therapies and tolerisation: slow disability worsening in relapsing and progressive MS
- Cell therapies and tolerisation: slow disability worsening in secondary progressive MS
- Dirucotide: reduce relapses and new lesions in relapsing MS
- Plovamer acetate: reduce relapses and new lesions in relapsing MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error